What question did this study set out to answer?

To evaluate the efficacy and safety of definitive chemoradiotherapy using concurrent S-1 and cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.

March 17, 2015Cancer ScienceOpen Access

Phase II trial of chemoradiotherapy with S‐1 plus cisplatin for unresectable locally advanced head and neck cancer ( JCOG 0706)

View Full Paper

Ask AI

Bookmark

Authors

MTMakoto TaharaNational Cancer Center Hospital East NKNaomi KiyotaKobe University Hospital JMJunki MizusawaNational Cancer Center Hospital East

Discussion

Member takes

Implication

Phase II trial demonstrates favorable survival with S-1 and cisplatin chemoradiotherapy in locally advanced head and neck cancer, suggesting a viable definitive regimen.

Key Points

To evaluate the efficacy and safety of definitive chemoradiotherapy using concurrent S-1 and cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Conducted an interventional phase II trial enrolling 45 patients with unresectable locally advanced disease.
Treatment consisted of concurrent radiation (70 Gy in 35 fractions) with two 5-week cycles of oral S-1 (60 mg/m²/day on days 1–14) and intravenous cisplatin (20 mg/m²/day on days 8–11), followed by two consolidation chemotherapy cycles for responders.
The primary endpoint was central review clinical complete remission, with median follow-up of 3.52 years.
Clinical complete remission was achieved in 64.4% of patients (8 complete responses, 21 good partial responses).
At 3 years, local progression-free survival was 62.2%, progression-free survival was 60.0%, overall survival was 64.4%, and time to treatment failure was 48.9%.
Frequent grade 3 to 4 toxicities included pharyngeal mucositis (46.7%), dysphagia (46.7%), oral mucositis (44.4%), anorexia (42.2%), radiation dermatitis (26.7%), and neutropenia (26.7%), with zero treatment-related deaths.

Cite This Study

Tahara et al. (2015) studied this question.

synapsesocial.com/papers/6a8a9c05176d2ac34cfbec81 https://doi.org/10.1111/cas.12657

View Full Paper

Ask AI

Bookmark

Implication

Phase II trial demonstrates favorable survival with S-1 and cisplatin chemoradiotherapy in locally advanced head and neck cancer, suggesting a viable definitive regimen.

Phase II trial of chemoradiotherapy with S‐1 plus cisplatin for unresectable locally advanced head and neck cancer ( JCOG 0706)

Discussion

Member takes

Implication

Key Points

Cite This Study

Phase II trial of chemoradiotherapy with S‐1 plus cisplatin for unresectable locally advanced head and neck cancer ( JCOG 0706)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider